The federal contract IDV award to Glaxosmithkline, LLC is for the supply of pediatric influenza vaccines to the Centers for Disease Control and Prevention (CDC) for distribution to immunization programs under the Section 317(j) Public Health Service Act and Vaccines for Children program. The single-award contract has a ceiling value of $161,025,000 and a period of performance from December 31, 2020 to February 28, 2022. The contract was issued in response to a CDC solicitation for a minimum order of 100 doses and a maximum of 50 million doses of pediatric influenza vaccines, to be delivered FOB destination to CDC distribution centers in Colorado and Tennessee. The contract does not include any set-aside designations. Glaxosmithkline, a global pharmaceutical company, has provided a range of vaccines, antiviral medications, and other products to U.S. government agencies through prior federal contracts and grants. The IDV award supports CDC's routine immunization programs and disease prevention efforts.
In addition to this pediatric influenza vaccine IDV, Glaxosmithkline holds other federal contract IDVs for related pharmaceutical products, including a $15 million contract with the VA National Acquisition Center for seasonal influenza vaccines, a $3 million CDC contract for vaccine storage and rotation services, and a $4.6 million Defense Logistics Agency contract for the antiviral medication zanamivir. Glaxosmithkline has also served as a subcontractor on a $280 million Department of Defense contract for COVID-19 monoclonal antibody therapeutics.
Generated 11/27/24, 9:05 AM